🔎 Trials Near Me

Beranda › Kanker Metastatik › Nebraska › Omaha

Uji klinis Kanker Metastatik di Omaha, NE

13 studi untuk Kanker Metastatik mencari peserta di lokasi sekitar Omaha (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Menerima pesertaFase 3
  • Research Site, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07205822

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Menerima pesertaFase 2/3
  • University of Nebraska Medical Center, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06943755

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Menerima pesertaFase 1
  • Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07277413

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Menerima pesertaFase 2
  • Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07007559

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Menerima pesertaFase 2/3
  • Nebraska Medicine, Omaha
  • Nebraska Medicine - Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06989437

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Menerima pesertaFase 3
  • Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06072612

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 2
  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06769698

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Menerima pesertaFase 3
  • Nebraska Methodist Hospital, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jun 2026 · NCT05208047

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Menerima pesertaFase 1
  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
  • XCancer Omaha / Urology Cancer Center, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT05283330

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • Nebraska Cancer Specialists, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT07030257

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Menerima pesertaFase 3
  • Nebraska Methodist Hospital, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Feb 2026 · NCT06127407

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Omaha
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

Menerima pesertaFase 1
  • Nebraska Cancer Specialists (NCS), Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Nov 2024 · NCT06190886

Uji klinis Kanker Metastatik di kota lain

Studi lain di Omaha

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.